Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Singulair

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Singulair was produced by Merck & Co..

India denies patent on Pfizer's Xeljanz

India denies patent on Pfizer's Xeljanz

Earlier cases have involved Novartis' cancer drug Glivec (imatinib), Roche 's Pegasys (peginterferon alfa-2a) for hepatitis, Merck &Co's asthma treatment Singulair (montelukast), Gilead's HIV drug Viread (tenofovir) and

Merck & Co's cancer drug Keytruda gaining traction in US

Merck & Co's cancer drug Keytruda gaining traction in US Merck's third-quarter results were hit as expected by the lingering effect of patent expiries on key products such as cancer drug Temodar (temozolomide) and Singulair (montelukast) for asthma, as

Merck cuts MK-3475 deals with Pfizer, Amgen and Incyte

Merck cuts MK-3475 deals with Pfizer, Amgen and Incyte sales of asthma drug Singulair (montelukast) on generic competition, as well as a 14 per cent drop in net income to $781m.

Who tops the pharma list?

Who tops the pharma list? By the end of 2012, Advair (GSK - $8.2bn), Singulair (Merck - $5.5bn) and Diovan (Novartis - $5.7bn) would be among many billion-dollar brands to lose exclusivity during the calendar

GSK loses patent on Tykerb in India

GSK loses patent on Tykerb in India This year has already seen IP setbacks in India for Novartis' leukaemia drug Glivec (imatinib), Merck &Co's Januvia (sitagliptin) diabetes franchise and Singulair (montelukast),   Roche's Pegasys (peginterferon alfa-2a),

1 2 3 4 5 6 7 8 9 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Apex.co.uk Conferences, Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Latest intelligence

04 A Healthy Ambience
Creating a Lifeline to the New Digital User...
03 Health Services
How Pharma Companies Can Survive the Patent Cliff Through Digital Innovation...
From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...

Infographics